Browse > Article
http://dx.doi.org/10.3746/jkfn.2014.43.1.047

Effects of Dietary Tea Polyphenol on Tumor Growth Inhibition by Cisplatin in EMT6 Breast Tumor-bearing Mice  

Lee, Byoung-Rai (Dept. of Biochemistry, College of Medicine, Chosun University)
Cho, Jung-Il (Dept. of Food Nutrient and Culinary, Chosun College of Science & Technology)
Park, Pyoung-Sim (Institute of Medical Science, Chosun University)
Publication Information
Journal of the Korean Society of Food Science and Nutrition / v.43, no.1, 2014 , pp. 47-54 More about this Journal
Abstract
The aim of this study is to evaluate the effects of green tea polyphenol (GTP) on anticancer treatment with cisplatin (CP), using both an in vitro cell culture model and an in vivo mouse model of established breast tumor. Mouse breast cancer cells (EMT6) were treated with or without GTP and CP followed by determination of the cell viability using an MTT assay. The relative cell viability of CP treated EMT6 cells was 96% at a 20 ${\mu}g/mL$ concentration of cisplatin; however, in combination with GTP (50 ${\mu}g/mL$), the cell viability decreased to 20% at the same concentration of CP (20 ${\mu}g/mL$). For the in vivo study, EMT6 cells were inoculated into Balb/c mice for the establishment of a tumor-bearing mice model. The tumor-bearing mice were treated with CP (5 mg/kg. i.p.) with or without dietary GTP (0.2% drinking water). Tumor growth was monitored by a measurement of tumor size using a digital caliper, and nephrotoxicity was determined by enzymatic and histological examinations. The levels of p53 and caspase-3 in tumor tissues were examined by a Western blot. In tumor-bearing mice treated with GTP plus CP, the increment of tumor volume showed a significant reduction, compared with CP or GTP alone. The levels of p53 and cleaved caspase-3 (caspase-3/p17) in tumor tissues of tumor-bearing mice were increased by CP and GTP compared to CP alone. In CP treated tumor-bearing mice, ${\gamma}$-glutamyltranspeptidase (GGT) and alkaline phosphatase (AP) activities were decreased, and marked tubular necrosis and dilatation were observed in the kidney. CP-induced enzymatic and histopathological changes in the kidney of tumor-bearing mice were reduced by combinations of GTP with CP. The results of these experiments demonstrated that dietary GTP has a potentiating effect on CP anti-tumor activity and a protective effect against CP-induced renal dysfunction. Therefore, GTP may be used as a modulator in anticancer treatment with CP.
Keywords
green tea; cisplatin; EMT6 cells; breast cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mishra BB, Tiwari VK. 2011. Natural products: an evolving role in future drug discovery. Eur J Med Chem 46: 4769-4807.   DOI   ScienceOn
2 Yang CS, Wang X. 2010. Green tea and cancer prevention. Nutr Cancer 62: 931-937.   DOI   ScienceOn
3 Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ. 1975. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59: 647-659.
4 Gupta S, Hussain T, Mukhtar H. 2003. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cells cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410: 177-185.   DOI   ScienceOn
5 Singh M, Bhui K, Singh R, Shukla Y. 2013. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci 93: 7-16.   DOI   ScienceOn
6 Luo T, Wang J, Yin Y, Hua H, Jing J, Sun X, Li M, Zhang Y, Jiang Y. 2010. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 12: R8. doi: 10.1186/bcr2473.   DOI   ScienceOn
7 Jordan P, Carmo-Fonseca M. 2000. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229-1235.   DOI   ScienceOn
8 Hartmann JT, Lipp HP. 2003. Toxicity of platinum compounds. Expert Opin Pharmacother 4: 889-901.   DOI   ScienceOn
9 Shamseddine AI, Farhat FS. 2011. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 57: 468-487.   DOI   ScienceOn
10 Fraser M, Chan SL, Chan SS, Fiscus RR, Tsang BK. 2006. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25: 2203-2212.   DOI   ScienceOn
11 Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. 2003. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22: 4851-4859.   DOI   ScienceOn
12 Fatima S, Arivarasu NA, Mahmood R. 2007. Vitamin C attenuates cisplatin-induced alterations in renal brush border membrane enzymes and phosphate transport. Hum Exp Toxicol 26: 419-426.   DOI   ScienceOn
13 Ateşşahín A, Ceríbaşi AO, Yuce A, Bulmus O, Cikim G. 2007. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100: 121-126.
14 El-Mowafy AM, Al-Gayyar MM, Salem HA, El-Mesery ME, Darweish MM. 2010. Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 17: 1067-1075.   DOI   ScienceOn
15 Sancho-Martinez SM, Prieto-Garcia L, Prieto M, Lopez- Novoa JM, Lopez-Hernandez FJ. 2012. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 136: 35-55.   DOI   ScienceOn
16 Bartelink H, Schellens JH, Verheij M. 2002. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 38: 216-222.   DOI   ScienceOn
17 Matsuyama R, Reddy S, Smith TJ. 2006. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24: 3490-3496.   DOI   ScienceOn
18 Lonning PE. 2010. Molecular basis for therapy resistance. Mol Oncol 4: 284-300.   DOI   ScienceOn
19 Vogl DT, Stadtmauer EA. 2006. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant 37: 985-987.   DOI   ScienceOn
20 Shrubsole MJ, Lu W, Chen Z, Shu XO, Zheng Y, Dai Q, Cai Q, Gu K, Ruan ZX, Gao YT, Zheng W. 2009. Drinking green tea modestly reduces breast cancer risk. J Nutr 139:310-316.
21 Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. 2007. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 245: 232-241.   DOI   ScienceOn
22 Chan MM, Soprano KJ, Weinstein K, Fong D. 2006. Epigallocatechin- 3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207: 389-396.   DOI   ScienceOn
23 Tenenhouse HS, Scriver CR, Vizel EJ. 1980. Alkaline phosphatase activity does not mediate phosphate transport in the renal-cortical brush-border membrane. Biochem J 190: 473-476.
24 Tate SS, Meister A. 1985. $\gamma$-Glutamyl transpeptidase from kidney. Methods Enzymol 113: 400-419.   DOI
25 Nessa MU, Beale P, Chan C, Yu JQ, Huq F. 2012. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res 32: 53-59.
26 Periasamy VS, Alshatwi AA. 2013. Tea polyphenols modulate antioxidant redox system on cisplatin-induced reactive oxygen species generation in a human breast cancer cell. Basic Clin Pharmacol Toxicol 112: 374-384.   DOI   ScienceOn
27 Graham HN. 1992. Green tea composition, consumption, and polyphenol chemistry. Prev Med 21: 334-350.   DOI   ScienceOn
28 Yee MS, Blakley BW, Begleiter A, Leith M. 2008. Delayed sodium thiosulphate administration reduces cisplatin efficacy on mouse EMT6 tumour cells in vitro. J Otolaryngol Head Neck Surg 37: 638-641.
29 Khan SA, Priyamvada S, Khan W, Khan S, Farooq N, Yusufi AN. 2009. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol Res 60:382-391.   DOI   ScienceOn
30 Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O. 2006. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 4: 211-219.   DOI   ScienceOn
31 Sladowski D, Steer SJ, Clothier RH, Balls M. 1993. An improved MTT assay. J Immunol Methods 157: 203-207.   DOI   ScienceOn